Share Price and Basic Stock Data
Last Updated: December 20, 2025, 3:47 am
| PEG Ratio | -0.31 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dipna Pharmachem Ltd operates within the pharmaceuticals industry, a sector known for its resilience and growth potential. The company’s reported sales figures reflect a positive trajectory, rising from ₹31 Cr in FY 2021 to ₹100 Cr in FY 2023. More recently, sales stood at ₹164 Cr for FY 2024, demonstrating a robust growth pattern. However, it’s worth noting that the trailing twelve months (TTM) revenue is projected to decline to ₹125 Cr in FY 2025. This decline raises questions about the sustainability of recent growth, especially as the company anticipates a drop to ₹34 Cr in the last quarter of FY 2025. With public ownership at a staggering 90.02%, it appears the market is largely driven by retail investor sentiment. The company’s ability to navigate this transition will be crucial as it seeks to maintain its current growth momentum.
Profitability and Efficiency Metrics
Profitability metrics for Dipna Pharmachem remain modest, with an operating profit margin (OPM) of just 2% in recent periods, which is below the industry standard. The reported net profit has been relatively stagnant, oscillating around ₹1 Cr for the last few fiscal years, translating to an earnings per share (EPS) of ₹0.41 for FY 2025. This low profitability can be a concern for investors, particularly given the high price-to-earnings (P/E) ratio of 18.6, which may suggest that the stock is overvalued in relation to its earnings. The cash conversion cycle (CCC) shows an impressive improvement, reported at -20 days, indicating that the company is efficiently managing its receivables and payables. This efficiency could be a silver lining, suggesting that while profitability is limited, operational efficiency is being prioritized.
Balance Sheet Strength and Financial Ratios
Diving into the balance sheet, Dipna Pharmachem carries a market capitalization of ₹38.1 Cr with total borrowings of ₹14 Cr, which reflects a manageable debt situation. The company’s current ratio stands at 1.56, suggesting a comfortable liquidity position for meeting short-term obligations. However, the return on equity (ROE) of 2.55% and return on capital employed (ROCE) of 6.64% are notably low, indicating that the company is not generating much return for its shareholders relative to its equity base. The price-to-book value ratio at 0.89x suggests that the stock is trading below its book value, which could be appealing to value investors looking for bargains. Overall, while the balance sheet appears stable, the low return metrics raise concerns about future profitability and growth potential.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dipna Pharmachem reveals a significant shift in promoter holdings, which have plummeted from 66.56% in September 2022 to just 9.98% by March 2024. This drastic reduction could signal concerns about the company’s governance or strategic direction, potentially eroding investor confidence. Public ownership has risen to 90.02%, reflecting a shift towards retail investors, which could lead to volatility in stock performance depending on market sentiment. The number of shareholders increased to 1,742, indicating growing interest among retail investors. However, the lack of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could be a red flag, suggesting that institutional interest in the company remains limited.
Outlook, Risks, and Final Insight
Looking ahead, Dipna Pharmachem faces a mixed outlook. On one hand, the company has shown commendable sales growth and operational efficiency, but these positives are overshadowed by low profitability and a concerning drop in promoter confidence. The anticipated decline in revenue for FY 2025 raises questions about the sustainability of its growth strategy. Investors should be cautious, as the high P/E ratio may indicate that the stock is overvalued given its current earnings. Risks such as fluctuating sales, low profit margins, and a lack of institutional backing could impact share price volatility. Therefore, while the company exhibits operational strengths, investors must weigh these against the potential risks before making investment decisions. Understanding the broader market dynamics and the company’s strategic responses will be key for those considering an investment in Dipna Pharmachem.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 235/84.3 | 33.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,413 Cr. | 405 | 479/192 | 91.4 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.7 Cr. | 48.2 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.3 Cr. | 33.0 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,162.24 Cr | 1,151.80 | 52.60 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 44 | 49 | 74 | 74 | 90 | 91 | 34 |
| Expenses | 28 | 42 | 48 | 73 | 73 | 88 | 89 | 32 |
| Operating Profit | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 |
| OPM % | 3% | 3% | 2% | 2% | 2% | 2% | 2% | 6% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
| Tax % | 25% | 26% | 26% | 27% | 27% | 21% | 26% | 34% |
| Net Profit | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 |
| EPS in Rs | 33.00 | 84.00 | 0.13 | 0.24 | 0.24 | 0.20 | 0.14 | 0.27 |
Last Updated: July 16, 2025, 10:10 am
Below is a detailed analysis of the quarterly data for Dipna Pharmachem Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 34.00 Cr.. The value appears to be declining and may need further review. It has decreased from 91.00 Cr. (Sep 2024) to 34.00 Cr., marking a decrease of 57.00 Cr..
- For Expenses, as of Mar 2025, the value is 32.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 89.00 Cr. (Sep 2024) to 32.00 Cr., marking a decrease of 57.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Sep 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Mar 2025, the value is 6.00%. The value appears strong and on an upward trend. It has increased from 2.00% (Sep 2024) to 6.00%, marking an increase of 4.00%.
- For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Interest, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
- For Depreciation, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Sep 2024) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Mar 2025, the value is 34.00%. The value appears to be increasing, which may not be favorable. It has increased from 26.00% (Sep 2024) to 34.00%, marking an increase of 8.00%.
- For Net Profit, as of Mar 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Sep 2024) to 1.00 Cr., marking an increase of 1.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.27. The value appears strong and on an upward trend. It has increased from 0.14 (Sep 2024) to 0.27, marking an increase of 0.13.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:50 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 20 | 30 | 31 | 73 | 100 | 164 | 125 | 108 |
| Expenses | 16 | 20 | 30 | 31 | 71 | 98 | 161 | 121 | 103 |
| Operating Profit | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 5 |
| OPM % | 2% | 2% | 1% | 1% | 3% | 2% | 2% | 3% | 5% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 3 |
| Tax % | 14% | 40% | 0% | 60% | 26% | 34% | 24% | 32% | |
| Net Profit | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 |
| EPS in Rs | 6.00 | 3.00 | 6.00 | 2.00 | 117.00 | 0.37 | 0.45 | 0.40 | 0.86 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% |
Dipna Pharmachem Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 20% |
| TTM: | -24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 74% |
| 3 Years: | -6% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 142% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 4% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 3:16 pm
Balance Sheet
Last Updated: December 4, 2025, 2:45 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 12 | 24 | 24 | 24 |
| Reserves | 0 | 0 | 1 | 1 | 2 | 12 | 13 | 14 | 35 |
| Borrowings | 5 | 6 | 10 | 12 | 10 | 16 | 19 | 17 | 14 |
| Other Liabilities | 6 | 8 | 8 | 12 | 24 | 37 | 76 | 77 | 105 |
| Total Liabilities | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 177 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 177 |
| Total Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 177 |
Below is a detailed analysis of the balance sheet data for Dipna Pharmachem Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00 Cr..
- For Reserves, as of Sep 2025, the value is 35.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2025) to 35.00 Cr., marking an increase of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 17.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 105.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 77.00 Cr. (Mar 2025) to 105.00 Cr., marking an increase of 28.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 177.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 132.00 Cr. (Mar 2025) to 177.00 Cr., marking an increase of 45.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 177.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Mar 2025) to 177.00 Cr., marking an increase of 45.00 Cr..
- For Total Assets, as of Sep 2025, the value is 177.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Mar 2025) to 177.00 Cr., marking an increase of 45.00 Cr..
Notably, the Reserves (35.00 Cr.) exceed the Borrowings (14.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -6.00 | -10.00 | -12.00 | -8.00 | -14.00 | -16.00 | -13.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 132 | 160 | 134 | 176 | 135 | 104 | 69 | 135 |
| Inventory Days | 112 | 66 | 70 | 89 | 34 | 72 | 86 | 88 |
| Days Payable | 142 | 148 | 105 | 145 | 123 | 139 | 172 | 243 |
| Cash Conversion Cycle | 103 | 78 | 99 | 120 | 46 | 38 | -17 | -20 |
| Working Capital Days | 3 | 6 | 44 | 47 | 37 | 108 | 80 | 137 |
| ROCE % | 8% | 5% | 3% | 17% | 9% | 7% | 7% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.41 | 0.45 | 260.55 | 333.40 | 6.91 |
| Diluted EPS (Rs.) | 0.41 | 0.45 | 260.55 | 333.40 | 6.91 |
| Cash EPS (Rs.) | 0.40 | 0.45 | 0.77 | 335.17 | 8.97 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.01 | 15.60 | 20.35 | 496.74 | 163.34 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.01 | 15.60 | 20.35 | 496.74 | 163.34 |
| Revenue From Operations / Share (Rs.) | 51.95 | 68.34 | 83.48 | 20787.26 | 8857.11 |
| PBDIT / Share (Rs.) | 1.43 | 1.43 | 1.96 | 644.23 | 118.66 |
| PBIT / Share (Rs.) | 1.43 | 1.42 | 1.95 | 642.46 | 116.60 |
| PBT / Share (Rs.) | 0.59 | 0.59 | 1.15 | 449.80 | 15.71 |
| Net Profit / Share (Rs.) | 0.40 | 0.45 | 0.76 | 333.40 | 6.91 |
| PBDIT Margin (%) | 2.75 | 2.08 | 2.35 | 3.09 | 1.33 |
| PBIT Margin (%) | 2.75 | 2.07 | 2.33 | 3.09 | 1.31 |
| PBT Margin (%) | 1.13 | 0.86 | 1.38 | 2.16 | 0.17 |
| Net Profit Margin (%) | 0.77 | 0.66 | 0.91 | 1.60 | 0.07 |
| Return on Networth / Equity (%) | 2.53 | 2.89 | 3.74 | 67.11 | 4.23 |
| Return on Capital Employeed (%) | 7.25 | 6.82 | 6.06 | 44.39 | 9.58 |
| Return On Assets (%) | 0.73 | 0.81 | 1.17 | 3.22 | 0.09 |
| Long Term Debt / Equity (X) | 0.23 | 0.33 | 0.58 | 1.91 | 6.44 |
| Total Debt / Equity (X) | 0.44 | 0.51 | 0.65 | 5.86 | 21.74 |
| Asset Turnover Ratio (%) | 0.94 | 1.56 | 1.76 | 2.38 | 1.43 |
| Current Ratio (X) | 1.56 | 1.60 | 1.99 | 1.16 | 1.21 |
| Quick Ratio (X) | 1.23 | 1.15 | 1.50 | 0.95 | 0.85 |
| Inventory Turnover Ratio (X) | 3.85 | 5.84 | 0.00 | 10.03 | 4.90 |
| Interest Coverage Ratio (X) | 1.71 | 1.72 | 2.46 | 3.34 | 1.18 |
| Interest Coverage Ratio (Post Tax) (X) | 1.48 | 1.54 | 1.95 | 2.73 | 1.07 |
| Enterprise Value (Cr.) | 51.18 | 28.22 | 25.24 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.40 | 0.17 | 0.25 | 0.00 | 0.00 |
| EV / EBITDA (X) | 14.85 | 8.22 | 10.74 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.27 | 0.13 | 0.15 | 0.00 | 0.00 |
| Price / BV (X) | 0.89 | 0.60 | 0.61 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.27 | 0.13 | 0.15 | 0.00 | 0.00 |
| EarningsYield | 0.02 | 0.04 | 0.06 | 0.00 | 0.00 |
After reviewing the key financial ratios for Dipna Pharmachem Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 0.45 (Mar 24) to 0.41, marking a decrease of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 0.45 (Mar 24) to 0.41, marking a decrease of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 3. It has decreased from 0.45 (Mar 24) to 0.40, marking a decrease of 0.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.01. It has increased from 15.60 (Mar 24) to 16.01, marking an increase of 0.41.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.01. It has increased from 15.60 (Mar 24) to 16.01, marking an increase of 0.41.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 51.95. It has decreased from 68.34 (Mar 24) to 51.95, marking a decrease of 16.39.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 2. There is no change compared to the previous period (Mar 24) which recorded 1.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is within the healthy range. It has increased from 1.42 (Mar 24) to 1.43, marking an increase of 0.01.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.59. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.59.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.40, marking a decrease of 0.05.
- For PBDIT Margin (%), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 10. It has increased from 2.08 (Mar 24) to 2.75, marking an increase of 0.67.
- For PBIT Margin (%), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 10. It has increased from 2.07 (Mar 24) to 2.75, marking an increase of 0.68.
- For PBT Margin (%), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 10. It has increased from 0.86 (Mar 24) to 1.13, marking an increase of 0.27.
- For Net Profit Margin (%), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 5. It has increased from 0.66 (Mar 24) to 0.77, marking an increase of 0.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is 2.53. This value is below the healthy minimum of 15. It has decreased from 2.89 (Mar 24) to 2.53, marking a decrease of 0.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.25. This value is below the healthy minimum of 10. It has increased from 6.82 (Mar 24) to 7.25, marking an increase of 0.43.
- For Return On Assets (%), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 5. It has decreased from 0.81 (Mar 24) to 0.73, marking a decrease of 0.08.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has decreased from 0.33 (Mar 24) to 0.23, marking a decrease of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has decreased from 0.51 (Mar 24) to 0.44, marking a decrease of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.94. It has decreased from 1.56 (Mar 24) to 0.94, marking a decrease of 0.62.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 1.60 (Mar 24) to 1.56, marking a decrease of 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 1.23. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 1.23, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.85. This value is below the healthy minimum of 4. It has decreased from 5.84 (Mar 24) to 3.85, marking a decrease of 1.99.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.71. This value is below the healthy minimum of 3. It has decreased from 1.72 (Mar 24) to 1.71, marking a decrease of 0.01.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.48. This value is below the healthy minimum of 3. It has decreased from 1.54 (Mar 24) to 1.48, marking a decrease of 0.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 51.18. It has increased from 28.22 (Mar 24) to 51.18, marking an increase of 22.96.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 1. It has increased from 0.17 (Mar 24) to 0.40, marking an increase of 0.23.
- For EV / EBITDA (X), as of Mar 25, the value is 14.85. This value is within the healthy range. It has increased from 8.22 (Mar 24) to 14.85, marking an increase of 6.63.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 24) to 0.27, marking an increase of 0.14.
- For Price / BV (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 1. It has increased from 0.60 (Mar 24) to 0.89, marking an increase of 0.29.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 24) to 0.27, marking an increase of 0.14.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dipna Pharmachem Ltd:
- Net Profit Margin: 0.77%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.25% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 2.53% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.48
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.23
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 19.1 (Industry average Stock P/E: 52.6)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.44
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.77%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A/211, Siddhi Vinayak Complex, Ahmedabad Gujarat 380055 | info@dipnapharmachem.com http://www.dipnapharmachem.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Keyur Dipakkumar Shah | Managing Director |
| Ms. Dipna Keyur Shah | Non Executive Director |
| Mr. Nirav Soni | Non Executive Director |
| Mr. Nandish Shaileshbhai Jani | Independent Director |
| Mr. Parin Bhavsar | Independent Director |
FAQ
What is the intrinsic value of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd's intrinsic value (as of 21 December 2025) is 9.74 which is 34.63% lower the current market price of 14.90, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 39.2 Cr. market cap, FY2025-2026 high/low of 26.3/7.18, reserves of ₹35 Cr, and liabilities of 177 Cr.
What is the Market Cap of Dipna Pharmachem Ltd?
The Market Cap of Dipna Pharmachem Ltd is 39.2 Cr..
What is the current Stock Price of Dipna Pharmachem Ltd as on 21 December 2025?
The current stock price of Dipna Pharmachem Ltd as on 21 December 2025 is 14.9.
What is the High / Low of Dipna Pharmachem Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dipna Pharmachem Ltd stocks is 26.3/7.18.
What is the Stock P/E of Dipna Pharmachem Ltd?
The Stock P/E of Dipna Pharmachem Ltd is 19.1.
What is the Book Value of Dipna Pharmachem Ltd?
The Book Value of Dipna Pharmachem Ltd is 24.5.
What is the Dividend Yield of Dipna Pharmachem Ltd?
The Dividend Yield of Dipna Pharmachem Ltd is 0.00 %.
What is the ROCE of Dipna Pharmachem Ltd?
The ROCE of Dipna Pharmachem Ltd is 6.64 %.
What is the ROE of Dipna Pharmachem Ltd?
The ROE of Dipna Pharmachem Ltd is 2.55 %.
What is the Face Value of Dipna Pharmachem Ltd?
The Face Value of Dipna Pharmachem Ltd is 10.0.